Ontology highlight
ABSTRACT:
SUBMITTER: Stilgenbauer S
PROVIDER: S-EPMC6087718 | biostudies-literature | 2018 Aug
REPOSITORIES: biostudies-literature
Stilgenbauer Stephan S Leblond Veronique V Foà Robin R Böttcher Sebastian S Ilhan Osman O Knauf Wolfgang W Mikuskova Eva E Renner Christoph C Tausch Eugen E Woszczyk Dariusz D Gresko Ekaterina E Lundberg Linda L Moore Tom T Morris Thea T Robson Susan S Bosch Francesc F
Leukemia 20180427 8
GREEN (NCT01905943) is a non-randomized, open-label phase IIIb study investigating obinutuzumab alone or plus chemotherapy in chronic lymphocytic leukemia (CLL). We report a preplanned subgroup analysis of 158 previously untreated CLL patients receiving obinutuzumab-bendamustine (G-B). Patients received six 28-day cycles (C) of G-B: obinutuzumab day (D)1/D2 of C1 (25 mg D1/975 mg D2), 1000 mg D8 and D15 of C1, and D1 of C2-6; and bendamustine 70/90 mg/m<sup>2</sup> D1 and D2 of C1-6. The primary ...[more]